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Pioderma gangrenoso bolhoso e síndrome mielodisplásica*
Mariana Dias Batista1 Ricardo Limongi Fernandes2 Marco Alexandre Dias da Rocha3
Juliana Kida Ikino4 Ronald Feitosa Pinheiro5 Maria de Lourdes Lopes Ferrari Chauffaille6
Nílceo Schwery Michalany7 Fernando Augusto de Almeida8
Abstract: Pyoderma gangrenosum can present as a cutaneous manifestation of paraneoplastic
syndromes. A case of bullous pyoderma gangrenosum associated with bicytopenia is
described. During the complementary investigation, myelogram, bone marrow biopsy and
karyotype were performed, and showed a pattern consistent with myelodysplastic syndrome.
The patient was treated with dapsone with improvement. Pyoderma gangrenosum can be a
manifestation of systemic diseases. The possibility of myelodysplastic syndrome should always
be considered in patients with pyoderma gangrenosum associated with cytopenia. Pyoderma
gangrenosum could indicate poorer prognosis in patients with systemic diseases. 
Keywords: Autoimmune diseases; Dapsone; Myelodysplastic syndromes; Pyoderma gan-
grenosum
Resumo: O pioderma gangrenoso pode apresentar-se como manifestação paraneoplásica.
Relata-se um caso de pioderma gangrenoso, da variante bolhosa, acompanhado de bici-
topenia, em que foi evidenciado, por meio de mielograma, biópsia de medula óssea e car-
iótipo, padrão compatível com síndrome mielodisplásica, subtipo citopenia refratária com
displasia de multilinhagens. Foi tratado com dapsona, obtendo cicatrização das lesões. O
pioderma gangrenoso pode associar-se a doenças sistêmicas, devendo a síndrome mielodis-
plásica ser considerada nos casos acompanhados de citopenias. Portanto, o pioderma gan-
grenoso pode ser um marcador cutâneo de doença sistêmica de prognóstico reservado. 
Palavras-chave: Dapsona; Doenças auto-imunes; Pioderma gangrenoso; Síndromes mielodis-
plásicas
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INTRODUCTION
Pyoderma gangrenosum (PG) is an uncommon
inflammatory disease, first described in 1930,1 that
begins with an erythematous nodule or hemorrhagic
pustule, evolving progressively to necrosis and pain-
ful ulcer with violaceous, undermined and irregular
borders, surrounded by an erythematous halo. There
can be single or multiple lesions, which typically pre-
sent cribriform scarring pattern.2 The pathergy phe-
nomenon has been frequently described associated to
the infection, in regards to the development of new
lesions or worsening of pre-existing lesions after dif-
ferent types of trauma, such as debridement, intrader-
mal injections, vaccinations, or surgical scars. This
phenomenon is found in up to 50% of patients.3
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pustules, vesicles containing blood, ulcerative and
vegetative lesions with undermined borders (the lar-
gest measuring five centimeters in diameter) and irre-
gular scars. The lesions were located on the chest and
upper limbs (Figures 1 and 2), including the palms.
He presented no adenomegaly or hepatosplenome-
galy upon examination. 
A biopsy of the lesion was performed, and the
pathological examination was characterized by diffu-
se chronic dermatitis in acute phase (Ziehl-Neelsen,
PAS and direct immunofluorescence were negative),
which was compatible with unspecific chronic ulcer.
Another biopsy was perfortmed and the outcome was
ulcerated suppurative chronic inflammatory process
with granulation tissue (absence of granulomas, and
Leishmania test was negative) (Figure 3). 
With a suggestive clinical picture and ruling
out differential diagnoses by pathological examina-
tion and other tests (serology for syphilis, HIV, HTLV,
leishmaniasis, bacterioscopy for mycobacteria on the
lesion and acid-fast bacilli in lymph – all tests were
negative), the presumptive diagnosis was bullous
pyoderma gangrenosum. The patient was submitted
to neoplasm screening since pyoderma gangrenosum
is usually present as paraneoplastic syndrome. 
In May 2003, the investigation was interrupted
because the patient suffered an acute myocardial
infarction and underwent left ventricular aneurys-
mectomy. The cardiac condition evolved satisfactorily
but he developed a crusty erythematous lesion on the
upper portion of the thoracotomy scar.
Resuming the investigation, general tests were
conducted, including complete blood count, which
showed bicytopenia (normocytic/normochronic ane-
mia and leukopenia), and proteinogram that showed
dysproteinemia (immunoglobulins A, G and M above
Atypical clinical forms of the disease were also descri-
bed, such as chronic vegetative, bullous, peristomal
and vulvar lesions.4 Bullous pyoderma gangrenosum
(BPG) is characterized by aggressive, painful lesions
with superficial vesicles that rupture to form typical
ulcerations with undermined borders.5 While classi-
cal PG is more frequently located on the lower limbs,
the bullous variant occurs chiefly on the upper
limbs.3
The diagnosis of PG is made by exclusion, and
it is necessary to investigate other causes of ulcerous
diseases, such as bacterial infections, mycobacterio-
ses, vascular insufficiency, vasculitis, halogen-derived
dermatosis, neoplasms and factitial dermatitis.6
Histopathological findings of PG are not specific,
encompassing areas with abscess,  areas with neutro-
philic and lymphocytic infiltrate, and with moderate
vasculitis with fibrinoid necrosis.7 In BPG, there is dif-
fuse neutrophilic dermatosis without primary vasculi-
tis.3 Direct immunofluorescence showed positive
perivascular pattern for antiC3 antobody in 83% of
cases, for antiIgM in 78%, for antiIgA in 14% and for
antiIgG in 11% of cases.4
The association between PG and systemic
diseases occurs in 50 to 75% of patients. The most
frequently associated diseases include inflammatory
bowel diseases, hematological neoplasias and rheu-
matoid artritis.7
PG associated to hematological disorders can
present atypical clinical characteristics, and the asso-
ciation with leukemia and myelodysplastic syndrome
(MDS) in the bullous form is frequently described.5
Up to 54% of the reported cases of PG associated with
leukemia were of the bullous subtype.8 The outbreak
of BPG can be an indication of reserved prognosis in
these diseases.5
The case reported shows the association bet-
ween PG, especially the bullous variant, and MDS, of
the refractory cytopenia with multilineage dysplasia
subtype (RCMD). In these cases, PG is the cutaneous
marker of the systemic disease with unfavorable diag-
nosis.
CASE REPORT
A male patient, 60 years-old, mullato, born and
living in the city of Campos Sales, State of Ceará, mar-
ried, farmer, was refered to the Dermatology Service
of Hospital Sao Paulo in March 2003, complaining of
skin lesions for one year. He complained of mild pain
on the lesion site. According to the patient, the
lesions were intermittent, and they receded sponta-
neously leaving a scar. He denied fever, nocturnal
sudoresis and gastrintestinal symptoms, as well as the
use of drugs. The dermatological exam showed
lesions in different phases: erythematous papules,
FIGURE 1: Ulcers with granulation tissue and
undermined borders on the chest
FIGURE 2:
Lesions at dif-
ferent deve-
lopment sta-
ges: ulcerati-
ve and vege-
tative lesions
with under-
mined bor-
ders, ulcerati-
ve and crusty
lesions and
irregular
scars on the
chest and
upper limbs
normal limits). The myelogram showed hypercellular
bone marrow with dysplasia in over 50% of cells from
the erythrocytic and granulocytic series, which is
compatible with RCMD, according to the World
Health Organization (WHO) classification.9 A biopsy
of the bone marrow revealed dysplastic alterations
and increased early granulocytic cells in the center of
intercellular spaces (Figure 4), associated to increa-
sed CD34 expression in the immunohistochemical
test (Figure 5). A G-band kariotyping showed 46 XY
[20][?]. The patient initiated treatment for the skin
condition with dapsone, 100mg per day, and the
lesions healed 45 days later. A multidisciplinary fol-
low-up will be conducted due to the risk of evolving
to myeloid leukemia.
DISCUSSION
Myelodysplastic syndromes (MDS) are clonal
hematological disorders clinically and morphologi-
cally characterized by ineffective hematopoesis. They
can present chronic course, lasting a few years, or suf-
fer leukemic transformation, which occurs in 40% of
cases.10 They are associated with auto-immune mani-
festations, such as thrombocytopenic purpura, vascu-
litis, chronic inflammatory demyelinating polyneuro-
pathy and PG, which occurs in 10 to 13.6% of cases.
These auto-immune manifestations represent a signi-
ficant cause of morbidity and mortality, and are asso-
ciated with poorer prognosis.11 The average survival
after diagnosis of MDS is 25 months; if auto-immune
manifestations occur, it drops to nine months. Auto-
immune manifestations respond to immunosuppres-
FIGURE 4: Photomicrography of histological section of bone mar-
row displays atypical megakaryocyte, some precursor granulocytic
cells and decreased erythroblastic series, with a left shift. Stroma
shows edema and fibrosis (HE 400X)
FIGURE 5: Photomicrography of histological section of bone marrow.
Immune-histochemical reaction with antibody CD34 showing
increased number of cells positive to antibodies (peroxidase 400X)
FIGURE 3: Photomicrography of histological section of skin shows
diffuse infiltrate with polymorphonuclear lymphocytes, histiocytes
and fibrinoid degeneration of the vascular wall (HE 100X)
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sant therapy; however, the clinical response is gene-
rally not sustained requiring progressively higher
doses of immunosuppressants.12
The case reported presents MDS of the RCMD
subtype.9 In an comprehensive literature review
through Medline, no descriptions were found on the
association with this subtype with PG.  
The pathogenesis of the relation between PG
and hematological disorders remains unclear.  MDS
would cause alterations in antigen presentation, in T-
cell response or in the interaction between T and B
cells, leading to an immune system imbalance,12
which would lead, in turn, to production of auto-anti-
bodies against cutaneous antigens with perivascular
immune complexe deposition.13 PG can occur conco-
mitant to the hematological disease or, during its evo-
lution, as marker of the malignant transformation of
a previously stable disease.8
As in the case reported, PG can be the cuta-
neous manifestation of a systemic disease. The possi-
bility of MDS should always be considered in patients
with pyoderma gangrenosum presenting by mono-,
bi- or pancytopenia. 
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